A PHASE 3, MULTI-SITE, RANDOMIZED, MIXED-BLIND, PARALLEL-GROUP TREATMENT WITHDRAWAL AND RE-TREATMENT STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ...

Mise à jour : Il y a 5 ans
Référence : EUCTR2010-020005-32

A PHASE 3, MULTI-SITE, RANDOMIZED, MIXED-BLIND, PARALLEL-GROUP TREATMENT WITHDRAWAL AND RE-TREATMENT STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

-To compare the efficacy responses of CP-690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP-690,550 treatment and subsequent withdrawal of active treatment at various timepoints during the 16-week double-blind active or placebo treatment period in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. -To evaluate the regain of efficacy responses of CP-690,550 (5 mg BID and 10 mg BID) following 4-16 weeks of CP-690,550 treatment withdrawal and subsequent re-treatment in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. -To evaluate the safety and tolerability of CP-690,550 (5 mg BID and 10 mg BID) in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.


Critère d'inclusion

  • Chronic plaque psoriasis